Johnson & Johnson stock (US4781601046): Revenue holds firm as new filing points to steady healthcare demand

Johnson & Johnson drew fresh investor attention on May 22 after a new filing highlighted quarterly revenue of $24.06 billion, while MarketBeat cited a consensus “Moderate Buy” rating and an average target of $253.04.

Johnson & Johnson attracted renewed attention on May 22 after a new filing cited quarterly revenue of $24.06 billion, net margin of 21.83%, and return on equity of 32.60%. For US investors, the company remains one of the most widely watched healthcare bellwethers, with exposure across pharmaceuticals and medtech according to MarketBeat as of 05/22/2026.

At the same time, MarketBeat said the stock carried a consensus rating of “Moderate Buy” and an average price target of $253.04. That matters because Johnson & Johnson is often used as a defensive benchmark in large-cap healthcare, where earnings quality, margin resilience, and cash generation tend to draw attention during periods of market volatility.

As of: 22.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Johnson & Johnson
• Sector/industry: Healthcare, pharmaceuticals and medical devices
• Headquarters/country: United States
• Core markets: U.S. and global healthcare markets
• Key revenue drivers: Innovative medicine and medtech
• Home exchange/listing venue: New York Stock Exchange (JNJ)
• Trading currency: USD

Johnson & Johnson: core business model

Johnson & Johnson operates across two major businesses that are closely tied to healthcare spending trends: Innovative Medicine and MedTech. The model gives the company multiple revenue streams, which can help soften pressure when one segment slows, especially for investors comparing it with more concentrated healthcare names.

The latest filing cited by MarketBeat points to a business that continues to generate substantial quarterly revenue and strong profitability metrics. For retail investors in the U.S., that combination often keeps Johnson & Johnson on watchlists as a lower-volatility way to track healthcare demand, reimbursement trends, and hospital and physician spending.

Main revenue and product drivers for Johnson & Johnson

Revenue in a company this size is usually driven by a mix of prescription medicines, oncology and immunology products, as well as surgical and orthopedic devices. The reporting cited on May 22 did not break out product-level sales in the summary available here, but it did show a quarterly top line of $24.06 billion, which indicates a large and diversified operating base.

Profitability also remains a central part of the investment case. A net margin of 21.83% suggests the company is still converting a meaningful portion of sales into profit, while return on equity of 32.60% points to efficient capital use. Those figures are useful context for U.S. investors who compare Johnson & Johnson with other large-cap healthcare names on earnings quality rather than only on headline growth.

MarketBeat also reported a consensus rating of “Moderate Buy” and an average target of $253.04. That does not change the underlying business facts, but it does show that the stock remains actively followed by analysts and market participants who focus on defensive growth and dividend-oriented portfolios.

Why Johnson & Johnson matters for US investors

Johnson & Johnson has a long-standing role in U.S. equity portfolios because it sits at the intersection of healthcare demand, innovation, and defensive investing. Its exposure to both pharmaceuticals and medical devices also gives it a broader operating profile than a single-product biotech company, which can matter when investors want sector diversification inside one stock.

The company is also relevant beyond the United States because its products are sold globally, but the stock’s size and liquidity make it especially important for American retail investors tracking the Dow-linked healthcare universe. In periods when the market rotates toward defensive sectors, names like Johnson & Johnson often become reference points for income and stability-focused strategies.

Conclusion

Johnson & Johnson remains in focus because its latest reported figures point to a large, profitable, and diversified healthcare franchise. The May 22 filing summary also showed that analysts continue to follow the name closely, with a “Moderate Buy” consensus in the MarketBeat feed cited here. For investors, the company’s importance lies less in a single headline and more in its combination of scale, profitability, and broad healthcare exposure.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.